Shots:

• The approval is based on P-III PACIFIC study assessing Imfinzi vs PBO in 713 ‘all-comer’ patients (regardless of PD-L1 status) with unresectable- Stage III- LA NSCLC whose disease had not progressed following concurrent platinum-based CRT
• The P-III PACIFIC study results: improvement in OS and PFS; 32% reduction in risk of death; mPFS (16.8 vs 5.6mos.)
• Imfinzi (durvalumab) is a mAb targeting PD-L1- blocking the interaction of PD-L1 with PD-1 and CD80- approved in 54 countries for stage III NSCLC following CRT

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: Daily Camera